DIA LAUNCHES NEW REGULATORY AFFAIRS CERTIFICATE PROGRAM

DIA LAUNCHES NEW REGULATORY AFFAIRS CERTIFICATE PROGRAM
HORSHAM, PA, USA-DECEMBER 28, 2010-DIA today announced the launch of its Regulatory Affairs Certificate Program. The Regulatory Affairs Certificate Program is the fourth certificate program developed by DIA.
DIA's Regulatory Affairs Certificate Program provides comprehensive training on current regulations and their practical application to the development and commercialization of pharmaceutical, biotechnology, medical device, and related health care products. The curriculum features courses in:
US Regulatory Affairs: IND and NDA/CTD Phases
EU Regulatory Requirements
Preparing for FDA Meetings
Post-approval Regulatory Requirements
Regulatory Requirements for Product Labeling and Advertising
Regulation of Drug, Medical Device, and Biologic Products
Quality Assurance
Other DIA Certificate Programs include:
Project Management
Clinical Research
Clinical Safety and Pharmacovigilance
"Our world-class faculty addresses the practical and theoretical aspects of the conduct of pharmacovigilance, with emphasis on understanding of the concepts, themes underlying effective processes, and the basic tenets of global regulatory compliance with safety principles," says Katie Hill, DIA Senior Training Manager.

Enroll in DIA's Regulatory Affairs Certificate Program.

ABOUT DIA
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies, and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China.
###

Suggested Articles

Colorado is making a play for a Japanese CDMO in hopes it will invest about $100 million in an empty AstraZeneca plant in Boulder.

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

The FDA approved Lundbeck's Vyepti, formerly known as eptinezumab, as the first IV therapy to prevent migraines in adults.